<DOC>
	<DOCNO>NCT02430181</DOCNO>
	<brief_summary>To Evaluate Safety Efficacy Lonafarnib without Ritonavir Boosting Adults With Genotype 1 Chronic Hepatitis D Virus ( HDV ) Infection ( LOWR-1 ) .</brief_summary>
	<brief_title>Lonafarnib With Without Ritonavir HDV ( LOWR-1 )</brief_title>
	<detailed_description>Chronic delta hepatitis serious form chronic liver disease cause infection hepatitis D virus ( HDV ) , small RNA virus require farnesylation major structural protein ( HDV antigen ) replication . Twenty-one subject chronic delta hepatitis randomize receive one seven different dos lonafarnib . Dosing occur 4-12 week , depend treatment arm , time , evidence antiviral response assess frequent measurement HDV-RNA . The primary therapeutic endpoint improvement quantitative serum HDV RNA level treatment lonafarnib therapy . The primary safety endpoint ability tolerate drug prescribe dose treatment duration . Several secondary endpoint measure , include side effect , ALT level , symptom . Therapy stop intolerance lonafarnib . This study design phase 2a study assess safety , tolerance antiviral activity seven dose combination lonafarnib without ritonavir boosting .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis D</mesh_term>
	<mesh_term>Hepatitis D , Chronic</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Males female , 18 65 year age diagnose HDV PCR Chronic hepatitis D infection , genotype 1 , document positive antiHDV Ab test least 6 month duration detectable HDV RNA PCR within 3 month study entry Liver biopsy within last two year Positive viral load quantitative PCR Electrocardiogram ( ECG ) show acute ischemia clinically significant abnormality QT/QTc interval &lt; 450 millisecond use Bazett 's correction Females childbearing potential ( intact uterus within 1 year since last menstrual period ) nonlactating negative serum pregnancy test . In addition , subject agree use one follow acceptable birth control method throughout study : 1. abstinence 2. surgical sterilization ( bilateral tubal ligation , hysterectomy , bilateral oophorectomy ) six month minimum 3 . IUD place least six month 4. barrier method ( condom diaphragm ) spermicide 5. surgical sterilization partner ( vasectomy six month ) 6. hormonal contraceptive least three month prior first dose study drug Willing able comply study procedure provide write informed consent Participation clinical trial use investigational agent within 30 day Study Visit 1 Patients coinfected HIV Patients screen test positive HCV , antiHIV Ab History decompensated cirrhosis within past year Active jaundice define total bilirubin &gt; 2.0 exclude Gilbert 's disease INR ≥ 1.5 Eating disorder alcohol abuse within past 2 year , excessive alcohol intake ( &gt; 20 g per day female ( 1.5 standard alcohol drink ) &gt; 30 g per day male ( 2.0 standard alcohol drink ) ( standard drink contain 14 g alcohol : 12 oz beer , 5 oz wine 1.5 oz spirit ) ( 1.0 fluid oz ( US ) = 29.57 mL ) . Drug abuse within last six month exception cannabinoids derivatives Patients absolute neutrophil count ( ANC ) &lt; 1500 cells/mm3 ; platelet count &lt; 100,000 cells/mm3 ; hemoglobin &lt; 12 g/dL woman &lt; 13 g/dL men ; abnormal TSH , T4 , T3 thyroid function adequately control ; serum creatinine concentration ≥ 1.5 time upper limit normal ( ULN ) History clinical evidence follow : 1. variceal bleeding , ascites , hepatic encephalopathy , CTP score &gt; 6 , decompensated liver disease form nonviral hepatitis 2. immunologically mediate disease ( e.g. , rheumatoid arthritis , inflammatory bowel disease , severe psoriasis , systemic lupus erythematosus ) require intermittent nonsteroidal antiinflammatory medication management require frequent prolong use corticosteroid ( inhaled asthma medication allow ) 3. malignancy within 3 year except basal cell skin cancer 4. significant unstable cardiac disease ( e.g. , angina , congestive heart failure , uncontrolled hypertension , history arrhythmia ) 5. chronic pulmonary disease ( e.g. , chronic obstructive pulmonary disease ) associate functional impairment 6. severe uncontrolled psychiatric disease , include severe depression , history suicidal ideation , suicidal attempt psychosis require medication and/or hospitalization 2 Patients body mass index &gt; 30 kg/m2 Concomitant drug know prolong QT interval</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>